Different perspectives on translational genomics in personalized medicine

gunel, tuba; Diz-Kucukkaya, Reyhan; göksever çelik, hale; Gumusoglu-Acar, Ece; Doğan, Berkcan

doi:10.4274/jtgga.galenos.2022.2021-11-4

Different perspectives on translational genomics in personalized medicine

Berkcan DOGAN, (Bursa Uludağ Üniversitesi, Tıp Fakültesi, Tıbbi Genetik Anabilim Dalı, Bursa, Türkiye)

Hale GOKSEVER CELIK, (Sağlık Bilimleri Üniversitesi, İstanbul Kanuni Sultan Süleyman Eğitimi ve Araştırma Hastanesi, Kadın Hastalıkları ve Doğum Anabilim Dalı, İstanbul, Türkiye)

Reyhan KÜÇÜKKAYA, (İstanbul Üniversitesi, Fen Fakültesi, Moleküler Biyoloji ve Genetik Bölümü, İstanbul, Türkiye)

ECE GÜMÜŞOĞLU, (İstanbul Üniversitesi, Fen Fakültesi, Moleküler Biyoloji ve Genetik Bölümü, İstanbul, Türkiye)

Tuba GÜNEL (İstanbul Üniversitesi, Fen Fakültesi, Moleküler Biyoloji ve Genetik Bölümü, İstanbul, Türkiye)

Journal of the Turkish-German Gynecological Association

0 0

Yıl: 2022 Cilt: 23 Sayı: 4 Sayfa Aralığı: 314 - 321 Metin Dili: İngilizce DOI: 10.4274/jtgga.galenos.2022.2021-11-4 İndeks Tarihi: 03-05-2023

Different perspectives on translational genomics in personalized medicine

Öz:

Personalized medicine is a relatively new and interesting concept in the medical and healthcare industries. New approaches in current research have supported the search for biomarkers, based on the genomic, epigenomic and proteomic profile of individuals, using new technological tools. This perspective involves the potential to determine optimal medical interventions and provide the optimal benefit-risk balance for treatment, whilst it also takes a patient’s personal situation into consideration. Translational genomics, a subfield of personalized medicine, is changing medical practice, by facilitating clinical or non-clinical screening tests, informing diagnoses and therapeutics, and routinely offering personalized health-risk assessments and personalized treatments. Further research into translational genomics will play a critical role in creating a new approach to cancer, pharmacogenomics, and women’s health. Our current knowledge may be used to develop new solutions that can be used to minimize, improve, manage, and delay the symptoms of diseases in real-time and maintain a healthy lifestyle. In this review, we define and discuss the current status of translational genomics in some special areas including integration into research and health care. (J Turk Ger Gynecol Assoc 2022; 23: 314-21)

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Maier M. Personalized medicine-a tradition in general practice. Eur J Gen Pract 2019; 25: 63-4.
2. Choi HK. Translational genomics and multi-omics integrated approaches as a useful strategy for crop breeding. Genes Genomics 2019; 41: 133-46.
3. Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff (Millwood) 2018; 37: 694-701.
4. Warren M. The approach to predictive medicine that is taking genomics research by storm. Nature 2018; 562: 181-3.
5. Zeggini E, Gloyn Al, Barton Ac, Wain VL. Translational genomics and precision medicine: moving from the lab to the clinic. Science 2019; 365: 1409-13.
6. Kussmann M, Kaput J. Translational genomics. Appl Transl Genom 2014; 10: 43-7.
7. Hood L, Rowen L. The Human Genome Project: big science transforms biology and medicine. Genome Med 2013; 5.
8. Al Kawam A, Sen A, Datta A, Dickey N. Understanding the Bioinformatics Challenges of Integrating Genomics into Healthcare. IEEE J Biomed Health Inform 2018; 22: 1672-83.
9. Pritchard DE, Moeckel F, Villa MS, Housman LT, McCarty CA, McLeod HL. Strategies for integrating personalized medicine into healthcare practice. Per Med 2017; 14: 141-52.
10. Di Resta C, Galbiati S, Carrera P, Ferrari M. Next-generation sequencing approach for the diagnosis of human diseases: open challenges and new opportunities. EJIFCC 2018; 29: 4-14.
11. Rabbani B, Mahdieh N, Hosomichi K, Nakaoka H, Inoue I. Next-generation sequencing: impact of exome sequencing in characterizing Mendelian disorders. J Hum Genet 2012; 57: 621-32.
12. Teer JK, Mullikin JC. Exome sequencing: the sweet spot before whole genomes. Hum Mol Genet 2010; 19: R145-51.
13. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Meth 2008; 5: 621-8.
14. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10: 57-63.
15. Furey TS. ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions. Nat Rev Genet 2012; 13: 840-52.
16. Park PJ. ChIP-seq: advantages and challenges of a maturing technology. Nat Rev Genet 2009; 10: 669-80.
17. Gonzaga-Jauregui C, Lupski JR, Gibbs RA. Human genome sequencing in health and disease. Annu Rev Med 2012; 63: 35-61.
18. Pasche B, Absher D. Whole-genome sequencing. JAMA 2011; 305: 1596-7.
19. Hambuch TM, Mayfield J, A Shankar, Hogue M, Mead CL, Ramos E. Clinical Genome Sequencing. In: Kulkarni S, Roy S, editors. Clinical Genomics. USA: Elsevier; 2015. p. 21-35.
20. Mehandziska S, Stajkovska A, Stavrevska M, Jakovleva K, Janevska M, Rosalia R, et al. Workflow for the Implementation of Precision Genomics in Healthcare. Front Genet 2020; 11: 619.
21. Mascia C, Uva P, Leo S, Zanetti G. OpenEHR modeling for genomics in clinical practice. Int J Med Inform 2018; 120: 147-56.
22. Ashley EA, Butte AJ, Wheeler MT, Chen R, Klein TE, Dewey FE, et al. Clinical assessment incorporating a personal genome. Lancet 2010; 375: 1525-35.
23. Lappalainen T, Scott AJ, Brandt M, Hall IM genomic analysis in the age of human genome sequencing. Cell 2019; 177: 70-84.
24. Brooks JD. Translational genomics: the challenge of developing cancer biomarkers. Genome Res 2012; 22: 183-7.
25. Bombard Y, Bach PB, Offit K. Translating genomics in cancer care. J Natl Compr Canc Netw 2013; 11: 1343-53.
26. Ong FS, Lin JC, Das K, Grosu DS, Fan JB. Translational utility of nextgeneration sequencing. Genomics 2013; 102: 137-9.
27. Patel L, Parker B, Yang D, Zhang W. Translational genomics in cancer research: converting profiles into personalized cancer medicine. Cancer Biol Med 2013; 10: 214-20.
28. Ashley EA. Towards precision medicine. Nat Rev Genet 2016; 17: 507-22.
29. Mardis ER. The translation of cancer genomics: time for a revolution in clinical cancer care. Genome Med 2014; 6: 22.
30. Sardanelli F, Podo F. Management of an inherited predisposition to breast cancer. N Engl J Med 2007;357: 1663.
31. Senturk N, Tuncel G, Dogan B, Aliyeva L, Dundar MS, Ozemri Sag S, et al. BRCA variations risk assessment in breast cancers using different artificial ıntelligence models. Genes (Basel) 2021; 12: 1774.
32. Weitzel JN, Blazer KR, Macdonald DJ, Culver JO, Offit K. Genetics, genomics, and cancer risk assessment: state of the art and future directions in the era of personalized medicine. CA Cancer J Clin 2011; 61: 327-59.
33. Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical cancer screening: past, present, and future. Sex Med Rev 2020; 8: 28-37.
34. Gaynon PS, Crotty ML, Sather HN, Bostrom BC, Nachman JB, Steinherz PG, et al. Expression of BCR-ABL, E2A-PBX1, and MLLAF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children’s Cancer Group initiative. Leuk Lymphoma 1997; 26: 57-65.
35. Marquet P, Longeray PH, Barlesi F; participants of round table N°1 of Giens XXX:, Ameye V, Augé P, Cazeneuve B, et al. Translational research: precision medicine, personalized medicine, targeted therapies: marketing or science? Therapie 2015; 70: 1-19.
36. Gunel T, Dogan B, Gumusoglu E, Hosseini MK, Topuz S, Aydinli K. Regulation of HMGA2 and KRAS genes in epithelial ovarian cancer by miRNA hsa-let-7d-3p. J Cancer Res Ther 2019; 15: 1321-7.
37. Hancer VS, Diz-Kucukkaya R, Aktan M. Overexpression of Fc mu receptor (FCMR, TOSO) gene in chronic lymphocytic leukemia patients. Med Oncol 2012; 29: 1068-72.
38. Palanduz S, Bayrak A, Sirma S, Vural B, Cefle K, Ucur A, et al. Comparison of the cytogenetic and molecular analyses in the assessment of imatinib response in chronic myelocytic leukemia. Genet Test Mol Biomarkers 2009; 13: 599-602.
39. Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomed Rep 2017; 7: 3-5.
40. Murali R, Grisham RN, Soslow RA. The roles of pathology in targeted therapy of women with gynecologic cancers. Gynecol Oncol 2018; 148: 213-21.
41. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 2020; 396: 565-82.
42. Peng XL, Jiang P. Bioinformatics approaches for Fetal DNA fraction estimation in noninvasive prenatal testing. Int J Mol Sci 2017; 18: 453.
43. Shah NM, Lai PF, Imami N, Johnson MR. Progesterone-Related Immune Modulation of Pregnancy and Labor. Front Endocrinol (Lausanne) 2019; 10: 198.
44. van Boeckel SR, Davidson DJ, Norman JE, Stock SJ. Cell-free fetal DNA and spontaneous preterm birth. Reproduction 2018; 155: R137-45.
45. Tanaka M, Tsujimoto Y, Goto K, Kumahara K, Onishi S, Iwanari S, et al. Preeclampsia before 20 weeks of gestation: a case report and review of the literature. CEN Case Rep 2015; 4: 55-60.
46. Kamali Simsek N, Benian A, Sevgin K, Ergun Y, Goksever Celik H, Karahuseyinoglu S, et al. Microrna analysis of human decidua mesenchymal stromal cells from preeclampsia patients. Placenta 2021; 10: 12-9.
47. Kaartokallio T, Wang J, Heinonen S, Kajantie E, Kivinen K, Pouta A, et al. Exome sequencing in pooled DNA samples to identify maternal pre-eclampsia risk variants. Sci Rep 2016; 6: 29085.
48. Thangaratinam S, Gallos ID, Meah N, Usman S, Ismail KM, Khan KS; TIPPS (Tests in Prediction of Pre-eclampsia’s Severity) Review Group. How accurate are maternal symptoms in predicting impending complications in women with preeclampsia? A systematic review and meta-analysis. Acta Obstet Gynecol Scand 2011; 90: 564-73.
49. Gavriilaki E, Brodsky RA. Complementopathies and precision medicine. J Clin Invest 2020; 130: 2152-63.
50. Quinney SK, Patil AS, Flockhart DA. Is personalized medicine achievable in obstetrics? Semin Perinatol 2014; 38: 534-40.
51. Yildirim GY, Celik HG, Koroglu N, Karakus E. Do ovarian reserve markers predict the subsequent pregnancy outcomes in women with recurrent pregnancy loss? Turk J Biochemis 2018; 43: 481-6.
52. Bashiri A, Halper KI, Orvieto R. Recurrent Implantation Failureupdate overview on etiology, diagnosis, treatment, and future directions. Reprod Biol Endocrinol 2018; 16: 121.
53. Coughlan C. What to do when good-quality embryos repeatedly fail to implant. Best Pract Res Clin Obstet Gynaecol 2018; 53: 48-59.
54. Maddirevula S, Awartani K, Coskun S, AlNaim LF, Ibrahim N, Abdulwahab F, et al. A genomics approach to females with infertility and recurrent pregnancy loss. Hum Genet 2020; 139: 605-13.
55. Corey L, Valente A, Wade K. Personalized medicine in gynecologic cancer: fact or fiction? Obstet Gynecol Clin North Am 2019; 46: 155- 63.
56. Crusz SM, Miller RE. Targeted therapies in gynaecological cancers. Histopathology 2020; 76: 157-70.
57. Van Nyen T, Moiola CP, Colas E, Annibali D, Amant F. Modeling endometrial cancer: past, present, and future. Int J Mol Sci 2018; 19: 2348.
58. Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications. Cancer Med 2018; 7: 5217-36.
59. Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T. Precision targeted therapy of ovarian cancer. J Control Release 2016; 243: 250-68.
60. Neto N, Cunha TM. Do hereditary syndrome-related gynecologic cancers have any specific features? Insights Imaging. 2015; 6: 545- 52.
61. Basu P, Mukhopadhyay A, Konishi I. Targeted therapy for gynecologic cancers: Toward the era of precision medicine. Int J Gynaecol Obstet. 2018; 143(Suppl2): 131-6.
62. Günel T, Gumusoglu E, Dogan B, Ertem FB, Hosseini MK, Cevik N, et al. Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer. Arch Gynecol Obstet 2018; 298: 1173-80.
63. Markman M. Genomic-Based Therapy of Gynecologic Malignancies. Acta Med Acad 2019; 48: 84-9.
64. Taylor HS. Precision menopausal medicine. Menopause 2017; 24: 482-3.
65. De Franciscis P, Colacurci N, Riemma G, Conte A, Pittana E, Guida M, et al. A nutraceutical approach to menopausal complaints. Medicina (Kaunas) 2019; 55: 544.
66. Sissung TM, English BC, Venzon D, Figg WD, Deeken JF. Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. Pharmacogenomics 2010; 11: 89-103.
67. Weinshilboum RM, Wang L. Pharmacogenomics: Precision medicine and drug response. Mayo Clin Proc 2017; 92: 1711-22.
68. Bishop JR. Pharmacogenetics. Handb Clin Neurol 2018; 147: 59-73.
69. Wijeyeratne YD, Heptinstall S. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol 2011; 72: 647-57.
70. Zhang X, Qi L, Liu Y. Aspirin in combination with clopidogrel in the treatment of acute myocardial infarction patients undergoing percutaneous coronary intervention. Pak J Med Sci 2019; 35: 348- 52.
71. Dean L. Clopidogrel Therapy and CYP2C19 Genotype. 2012 Mar 8 (Updated 2018 Apr 18). In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
72. Klein MD, Lee CR, Stouffer GA. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. Pharmacogenomics 2018; 19: 1039-46.
73. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018; 39: 213-60.
74. Mukerjee G, Huston A, Kabakchiev B, Piquette-Miller M, van Schaik R, Dorfman R. User considerations in assessing pharmacogenomic tests and their clinical support tools. NPJ Genom Med 2018; 3: 26.
75. Rodríguez-Vicente AE, Lumbreras E, Hernandez JM, Martín M, Calles A, López Otín C, et al. Pharmacogenetics and pharmacogenomics as tools in cancer therapy. Drug Metab Pers Ther 2016; 31: 25-34.
76. Calvo E, Walko C, Dees EC, Valenzuela B. Pharmacogenomics, pharmacokinetics, and pharmacodynamics in the era of targeted therapies. Am Soc Clin Oncol Educ Book. 2016; 35: e175-84.

APA	Doğan B, göksever çelik h, Diz-Kucukkaya R, Gumusoglu-Acar E, gunel t (2022). Different perspectives on translational genomics in personalized medicine. , 314 - 321. 10.4274/jtgga.galenos.2022.2021-11-4
Chicago	Doğan Berkcan,göksever çelik hale,Diz-Kucukkaya Reyhan,Gumusoglu-Acar Ece,gunel tuba Different perspectives on translational genomics in personalized medicine. (2022): 314 - 321. 10.4274/jtgga.galenos.2022.2021-11-4
MLA	Doğan Berkcan,göksever çelik hale,Diz-Kucukkaya Reyhan,Gumusoglu-Acar Ece,gunel tuba Different perspectives on translational genomics in personalized medicine. , 2022, ss.314 - 321. 10.4274/jtgga.galenos.2022.2021-11-4
AMA	Doğan B,göksever çelik h,Diz-Kucukkaya R,Gumusoglu-Acar E,gunel t Different perspectives on translational genomics in personalized medicine. . 2022; 314 - 321. 10.4274/jtgga.galenos.2022.2021-11-4
Vancouver	Doğan B,göksever çelik h,Diz-Kucukkaya R,Gumusoglu-Acar E,gunel t Different perspectives on translational genomics in personalized medicine. . 2022; 314 - 321. 10.4274/jtgga.galenos.2022.2021-11-4
IEEE	Doğan B,göksever çelik h,Diz-Kucukkaya R,Gumusoglu-Acar E,gunel t "Different perspectives on translational genomics in personalized medicine." , ss.314 - 321, 2022. 10.4274/jtgga.galenos.2022.2021-11-4
ISNAD	Doğan, Berkcan vd. "Different perspectives on translational genomics in personalized medicine". (2022), 314-321. https://doi.org/10.4274/jtgga.galenos.2022.2021-11-4

APA	Doğan B, göksever çelik h, Diz-Kucukkaya R, Gumusoglu-Acar E, gunel t (2022). Different perspectives on translational genomics in personalized medicine. Journal of the Turkish-German Gynecological Association, 23(4), 314 - 321. 10.4274/jtgga.galenos.2022.2021-11-4
Chicago	Doğan Berkcan,göksever çelik hale,Diz-Kucukkaya Reyhan,Gumusoglu-Acar Ece,gunel tuba Different perspectives on translational genomics in personalized medicine. Journal of the Turkish-German Gynecological Association 23, no.4 (2022): 314 - 321. 10.4274/jtgga.galenos.2022.2021-11-4
MLA	Doğan Berkcan,göksever çelik hale,Diz-Kucukkaya Reyhan,Gumusoglu-Acar Ece,gunel tuba Different perspectives on translational genomics in personalized medicine. Journal of the Turkish-German Gynecological Association, vol.23, no.4, 2022, ss.314 - 321. 10.4274/jtgga.galenos.2022.2021-11-4
AMA	Doğan B,göksever çelik h,Diz-Kucukkaya R,Gumusoglu-Acar E,gunel t Different perspectives on translational genomics in personalized medicine. Journal of the Turkish-German Gynecological Association. 2022; 23(4): 314 - 321. 10.4274/jtgga.galenos.2022.2021-11-4
Vancouver	Doğan B,göksever çelik h,Diz-Kucukkaya R,Gumusoglu-Acar E,gunel t Different perspectives on translational genomics in personalized medicine. Journal of the Turkish-German Gynecological Association. 2022; 23(4): 314 - 321. 10.4274/jtgga.galenos.2022.2021-11-4
IEEE	Doğan B,göksever çelik h,Diz-Kucukkaya R,Gumusoglu-Acar E,gunel t "Different perspectives on translational genomics in personalized medicine." Journal of the Turkish-German Gynecological Association, 23, ss.314 - 321, 2022. 10.4274/jtgga.galenos.2022.2021-11-4
ISNAD	Doğan, Berkcan vd. "Different perspectives on translational genomics in personalized medicine". Journal of the Turkish-German Gynecological Association 23/4 (2022), 314-321. https://doi.org/10.4274/jtgga.galenos.2022.2021-11-4